Introduction
Material and methods
Search strategy
Inclusion and exclusion criteria
Critical appraisal and data extraction
Statistical analysis
Results
Article selection
Critical appraisal
Year/first author | Risk of bias | Applicability concerns | |||||||
---|---|---|---|---|---|---|---|---|---|
Patient selection | Index test | Reference standard | Flow and timing | Patient selection | Index test | Reference standard | |||
2012 Huang | + | + | + | + | Low risk | + | + | + | Applicable for review |
2011 Sugahara | + | + | + | + | + | + | + | ||
2011 Pathare | + | + | + | + | + | + | + | ||
2011 Michikawaa
| + | + | + | + | + | + | + | ||
2011 Mahdey | + | + | + | + | + | + | + | ||
2009 Shah | + | + | + | + | + | + | + | ||
2005 Myoa
| + | + | + | + | + | + | + | ||
2003 Miyamotoa
| + | + | + | + | + | + | + | ||
2002 Takes | + | + | + | + | + | + | + | ||
2014 Hanken | + | + | + | − | Moderate risk | + | + | + | |
2013 Yoshioka | − | + | + | + | + | + | + | ||
2010 Prapinjumrune | + | − | + | + | + | + | + | ||
2007 Maahs | + | ? | + | + | + | + | + | ||
2005 Rodolico | + | + | + | − | + | + | + | ||
2002 Goto | ? | + | + | + | + | + | + | ||
2001 Fujii | + | + | + | − | + | + | + | ||
1999 Bova | − | + | + | + | + | + | + | ||
1999 Kuo | + | ? | + | + | + | + | + | ||
2013 Pattje | + | + | + | + | Low risk | − | + | + | Not applicable for review |
2004 Do | + | + | + | + | − | + | + | ||
2000 Rodrigo | + | + | + | + | − | + | + | ||
1997 Mullera
| + | + | + | + | − | + | + | ||
1997 Fortin | + | + | + | + | − | + | + | ||
2013 Fan | − | + | + | + | Moderate risk | − | + | + | |
2013 Li | + | + | ? | + | + | + | ? | ||
2012 Rasamny | + | + | − | + | − | + | − | ||
2011 Das | + | + | ? | + | + | + | ? | ||
2006 Wang | + | + | ? | + | + | + | ? | ||
2005 Shiraki | + | + | − | + | + | + | − | ||
2005 Soni | + | + | − | + | + | + | − | ||
2003 Vora | + | + | ? | + | − | + | ? | ||
2000 Capaccio | − | + | + | + | − | + | + | ||
2000 Mineta | + | + | −b
| + | + | + | − | ||
1997 Kyomoto | + | + | − | + | − | + | − | ||
1994 Mullera
| − | + | + | + | − | + | + | ||
1994 Parise | ? | + | + | + | − | + | + | ||
2014 Pickhard | + | ? | + | ? | High risk | − | − | + | |
2013 Zhong | + | + | − | − | + | + | − | ||
2010 Yamada | − | + | ? | + | + | + | ? | ||
2009 Liu | − | + | ? | − | + | + | ? | ||
2007 Xia | − | + | ? | + | + | + | ? | ||
2006 Zhou | − | − | + | + | + | − | + | ||
2004 Liu | ? | + | − | + | + | + | − | ||
2004 Chen | − | + | ? | − | + | + | ? | ||
2002 de Vicente | − | + | ? | + | + | + | ? | ||
2002 Namazie | − | + | ? | − | − | + | ? | ||
1999 Alavi | + | + | ? | ? | − | + | ? | ||
1995 Meredith | ? | ? | ? | − | − | − | ? | ||
1995 Rubin | ? | + | ? | + | + | + | ? | ||
1994 Volling | ? | ? | ? | + | − | ? | ? |
First author | Year | Country | Sample size | Tumor site | TNM stage | Reference standard | Nodal metastasis a
| Genes | Method | Tissue | Cutoff | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene amplification | Hanken | 2014 | Germany | 255 | Oral cavity | All | pN | 46 % | CCND1 | FISH | FFPE | G/C ratio >2.0 |
Yoshioka | 2013 | Japan | 25 | Oral cavity | All | pN | 60 % | 11q13.3 | CGH | FFPE | G/C ratio >1.12 | |
Sugahara | 2011 | Japan | 54 | Oral cavity | All | pN | 41 % | 11 genes in 11q13c
| CGH | Fresh frozen | G/C ratio >1.5 in ≥3 genes | |
Pathare | 2011 | India | 97 | Oral cavity | N.A. | pN | 56 % | 11q13 | CGH | Fresh frozen | G/C ratio >1.25 | |
Michikawa | 2011 | Japan | 127 | Oral cavity | All | pN | 42 % | CCND1 | FISH | Fixed FNA | G/C ratio >1.2 and gene/cell ratio >3 | |
Mahdey | 2011 | Malaysia | 50 | Cheek and tongue | All | pN | 54 % | CCND1 | FISH | FFPE | G/C Ratio >2.0 | |
Prapinjumruneb
| 2010 | Japan | 60 | Tongue | T1-2 | pN or FU | 43 % | FADD | RT-PCR | FFPE | G/C ratio >1.5 | |
Myo | 2005 | Japan | 45 | Oral cavity | cT1-2N0 | pN or FU | 38 % | CCND1 | FISH | Fixed FNA | >20 % of 100 cells ≥3 spots | |
Fujii | 2001 | Japan | 23 | Tongue | All | pN or FU | 61 % | CCND1 | FISH | FFPE | >20 % of 100 cells ≥3 spots | |
Protein overexpression | Huang | 2012 | Taiwan | 264 | Oral cavity | All | pN | 48 % | CCND1 | IHC | FFPE | 10 % staining |
Prapinjumrune b
| 2010 | Japan | 60 | Tongue | T1-2 | pN or FU | 40 % | FADD | IHC | FFPE | 29.2 % staining | |
Shah | 2009 | India | 135 | Cheek and tongue | All | pN | 33 % | CCND1 | IHC | FFPE | 10 % staining | |
Maahs | 2007 | Brazil | 45 | Oral cavity | All | pN | 51 % | CCND1 | IHC | FFPE | 1 % staining | |
Rodolico | 2005 | Italy | 97 | Lower lip | Any T cN0 | pN | 13 % | CCND1 | IHC | FFPE | 1 % staining | |
Miyamoto b
| 2003 | Japan | 41 | Oral cavity | All | pN | 20 % | CCND1 | IHC | FFPE | 10 % staining | |
Takes | 2002 | Netherlands | 52 | Oral cavity | All | pN | 63 % | CCND1 | IHC | FFPE | 5 % staining | |
Goto | 2002 | Japan | 41 | Tongue | cT1-2 | pN | 44 % | CCND1 | IHC | FFPE | 33 % staining | |
Kuo | 1999 | Taiwan | 88 | Oral cavity | All | pN | 60 % | CCND1 | IHC | FFPE | 10 % staining | |
Bova | 1999 | Australia | 147 | Tongue | All | pN | 23 % | CCND1 | IHC | FFPE | 10 % staining |
Study characteristics
Diagnostic value of 11q13 amplification region or individual genes located on 11q13 in detection of nodal metastasis
Study | Nodal metastasisa
| Threshold for amplification | Amplification | OR (95 % CI) |
p value | NPV (%) | PPV (%) | AC (%) | SE | SP |
---|---|---|---|---|---|---|---|---|---|---|
Hanken et al. | 117/255, 46 % | G/C ratio >2.0 | 69/255, 27 % | 1.66 (0.95–2.90) | 0.074 | 57 | 55 | 57 | 32 | 77 |
Yoshioka et al. | 15/25, 60 % | G/C ratio >1.12 | 13/25, 52 % | 1.14 (0.23–5.67) | 0.870 | 42 | 62 | 52 | 53 | 50 |
Sugahara et al. | 22/54, 41 % | G/C ratio >1.5 in ≥3 genes | 14/54, 26 % | 5.83 (1.52–22.33) | 0.010 | 70 | 71 | 70 | 45 | 88 |
Pathare et al. | 54/97, 56 % | G/C ratio >1.25 | 40/97, 41 % | 1.35 (0.60–3.06) | 0.473 | 47 | 60 | 53 | 44 | 63 |
Michikawa et al. | 53/127, 42 % | G/C ratio >1.2 and gene/cell ratio >3 | 43/127, 34 % | 2.78 (1.30–5.92) | 0.008 | 67 | 58 | 64 | 47 | 76 |
Mahdey et al. | 27/50, 54 % | G/C ratio >2.0 | 36/50, 72 % | 1.87 (0.54–6.51) | 0.327 | 57 | 58 | 58 | 78 | 35 |
Prapinjumrune et al. | 13/30, 43 % | G/C ratio >1.5 | 13/30, 43 % | 0.70 (0.16–3.05) | 0.638 | 53 | 38 | 47 | 38 | 53 |
Myo et al. | 17/45, 38 % | >20 % of 100 cells ≥3 spots | 15/45, 33 % | 20 (4.09–97.90) | <0.001 | 83 | 80 | 82 | 71 | 89 |
Fujii et al. | 14/23, 61 % | >20 % of 100 cells ≥3 spots | 13/23, 57 % | 0.50 (0.09–2.84) | 0.434 | 30 | 54 | 43 | 50 | 33 |
Diagnostic value of 11q13 overexpression in detection of nodal metastasis
Study | Nodal metastasisa
| Threshold for overexpression | Overexpression | Primary antibody | OR (95 % CI) |
p value | NPV (%) | PPV (%) | AC (%) | SE | SP |
---|---|---|---|---|---|---|---|---|---|---|---|
Huang et al. | 126/264, 48 % | 10 % staining | 97/264, 37 % | Monoclonal, SP4 | 2.48 (1.48–4.15) | 0.001 | 73 | 48 | 61 | 62 | 60 |
Prapinjumrune et al. | 24/60, 40 % | 29.2 % staining | 40/60, 66 % | Monoclonal, 1/FADD | 4.00 (1.14–14.09) | 0.025 | 44 | 83 | 60 | 50 | 80 |
Shah et al. | 44/135, 33 % | 10 % staining | 43/135, 32 % | Monoclonal, P2D11F11 | 1.35 (0.63–2.90) | 0.435 | 70 | 37 | 59 | 36 | 70 |
Maahs et al. | 23/45, 51 % | 1 % staining | 15/45, 33 % | N.A. | 1.71 (0.49–6.03) | 0.401 | 53 | 60 | 56 | 39 | 73 |
Rodolico et al. | 13/97, 13 % | 1 % staining | 65/97, 67 % | Monoclonal, DCS-6 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. |
Miyamoto et al. | 8/41, 20 % | 10 % staining | 27/41, 66 % | Monoclonal, DCS-6 | 1.71 (0.30–9.87) | 0.546 | 36 | 75 | 44 | 22 | 86 |
Takes et al. | 33/52, 63 % | 5 % staining | 30/52, 58 % | Monoclonal, DCS-6 | 0.70 (0.22–2.23) | 0.546 | 32 | 60 | 48 | 54 | 37 |
Goto et al. | 18/41, 44 % | 33 % staining | 14/41, 34 % | Monoclonal, DCS-6 | 3.60 (0.93–13.95) | 0.064 | 67 | 64 | 66 | 50 | 78 |
Kuo et al. | 53/88, 60 % | 10 % staining | 73/88, 83 % | Polyclonal, N.A. | 1.41 (0.46–4.30) | 0.550 | 47 | 62 | 59 | 85 | 20 |
Bova et al. | 34/147, 23 % | 10 % staining | 100/147, 68 % | Monoclonal, D1-GM | 3.43 (1.23–9.54) | 0.018 | 37 | 85 | 48 | 29 | 89 |
Meta-analysis | Q-value | df (Q) |
p value | I2
|
---|---|---|---|---|
Cyclin D1 overexpression (IHC) | 7.086 | 7 | 0.420 | 1.212 |
CCND1 amplification (FISH) | 11.597 | 4 | 0.021 | 65.509 |
11q13 amplification (CGH) | 3.727 | 2 | 0.155 | 46.341 |